ABVC BioPharma Inc

-0.01 (-0.78%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)29.37M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.03 Million
Adjusted EPS-$0.20
See more estimates
10-Day MA$0.89
50-Day MA$0.84
200-Day MA$1.87
See more pivots

ABVC BioPharma Inc Stock, NASDAQ:ABVC

44370 Old Warm Springs boulevard, 44370 Old Warm Springs Boulevard, Fremont, California 94538
United States of America
Phone: +1.510.668.0881
Number of Employees: 30


ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The firm's product pipeline includes ABV-1501, which is a combination therapy for triple negative breast cancer, ABV-1504, which is a botanical reuptake inhibitor that targets norepinephrine, ABV-1505 for treating attention deficit hyperactivity disorder, ABV-1702 to treat myelodysplastic syndromes, ABV-1703 for Pancreatic Cancer, ABV-1601 for treating depression in cancer patients, ABV-1701, which is a vitreous substitute for vitrectomy, ABV-2001, and ABV-2002. The company was founded in 1990 and is headquartered in Fremont, CA.